African Pioneer Share Discussion Threads

[typo56] 19/9/2005 20:00

It looks like a major holding changed hands today - about 8.36%, which looks like LDC.

I wonder if these trades have anything to do with Torex Retail (TRX) and/or Chris Moore. There were also some high volume trades in TRX today. I can't help thinking that ASP is in their sights.

[currypasty] 19/9/2005 15:06

something set the price off today !

[currypasty] 19/8/2005 09:30

Ascribe plc, the health IT group focusing on medicines management, will be
announcing its maiden preliminary results for the year ended 30 June 2005 on
Friday 23 September 2005

[currypasty] 18/7/2005 09:06

yes, I think it started in the Mail on Sunday..

if it is a bid target, i would hope for alot more than 40p

[barnsey] 18/7/2005 09:03

We tipped shares in XN Checkout at 280p in March when we reckoned that, despite their excellent run, it was still not too late take part in a remarkable recovery story. XN, which supplies cash till technology to the leisure sector, is now on the receiving end of a takeover bid from an acquisitive rival, Torex Retail. Eyebrows were raised when the Torex offer valued XN at just 265p a share.

Disappointed shareholders thought they had been short-changed and noted that XN's non-executive chairman, Chris Moore, is also chief executive of Torex Retail and a major shareholder in XN.

Such concern has subsided. Because the offer is in the form of Torex shares, XN's fortunes are now tied to those of the bidder, and XN's shares now trade at 290p.

This looks like a done deal as Torex already has acceptances from holders of 38.5% of XN's shares.
From the Financial Mail on sunday
For your information, i do not hold.
Investors meet on July 27 to approve the takeover, with the first closing date for acceptances two days later.

By coincidence, Moore was recently appointed non-executive chairman of Ascribe, a software company specialising in medicine management and another recent Midas selection.

Tipped at 27½p, the shares are now worth 32p. Torex is very much on the acquisition trail, but surely lightning won't strike twice with a bid for Ascribe?

C

[currypasty] 18/7/2005 08:22

Big rise today !

[currypasty] 08/7/2005 10:45

nice to see the directors have a vested interest in getting the shareprice up

[currypasty] 08/7/2005 10:45

RNS Number:6627O
Ascribe plc
08 July 2005

8th July 2005



ASCRIBE PLC (the "Company")



DIRECTOR SHAREHOLDING





The Company was yesterday informed that Stephen Critchlow, a director of the
Company, has yesterday transferred 128,000 ordinary shares of 1p each ("Ordinary
Shares") to his pension fund. Mr Critchlow's interest is unchanged following
this transfer and stands at 17,366,062 Ordinary Shares, which represents 16.8
per cent. of the Company's current issued share capital.

[currypasty] 22/6/2005 07:38

RNS Number:8775N
Ascribe plc
22 June 2005



22 June 2005


Ascribe plc (Ascribe) makes further strategic acquisitions
in medicines management IT


The Board of Ascribe, the health IT group focusing on medicines management,
announces today that it has further strengthened its market position in
medicines management IT by acquiring Park Systems Limited ("Park"), the largest
independent supplier of retail pharmacy computer systems in the UK, for a
maximum consideration of #0.4 million. The consideration will be satisfied by a
mixture of cash and new ordinary shares.


Park Systems was founded in 1981 and rapidly expanded to become one of today's
leading producers of high-quality, easy to use, retail pharmacy systems
including labelling, (EPoS - Electronic Point of Sale) and PMR (Patient
Medication Records). The system is used in all aspects of retail pharmacy
throughout the UK and worldwide. Significantly, Park's PMR equipment allows
pharmacists to view a patient's historic and current medication records to
ensure that that they receive the correct prescriptions, much in the same way as
Ascribe's software solutions for hospital pharmacies through its subsidiary ASC
Computer Software Limited ("ASC").


Following the completion of the acquisition, Liverpool-based Park Systems will
immediately move to Ascribe's Bolton Headquarters where it will merge with ASC.
The Board anticipates that this will result in significant synergies for the
enlarged division with the use of one software solution for both markets.


For the year ended 31 March 2005, Park reported sales of #246,000 with a small
profit.


Commenting, Stephen Critchlow, Chief Executive of Ascribe, said: "This
announcement is a further example of how Ascribe continues to deliver on its
stated growth strategy of expanding the Company's business activities in
complementary areas of medicines management IT. Park is a successful, market
leading company in retail pharmacy solutions, which is a core component of the
overall market we address."


In addition, Ascribe also announces today that it has acquired Archive Limited,
a supplier of software to its Protechnic Exeter subsidiary for a maximum
consideration of #107,000.


This follows the successful acquisition of Footman Walker on 23 May 2005, a
market leading supplier of clinical information systems into Accident &
Emergency and minor injury units for #2.6 million.


Contacts:


Ascribe plc Tel: [phone]

Stephen Critchlow

Chief Executive



Jeremy Lee Tel: [phone]

Group Finance Director



Citigate Dewe Rogerson Tel: [phone]

Ginny Pulbrook

Justin Griffiths


Notes to Editors:


Ascribe is a health IT group focusing on medicines management through the
development and marketing of software solutions supporting patient, clinical and
business processes to the international healthcare market. The Group consists
of ASC Computer Software Limited, a software supplier to hospital pharmacy
departments internationally and Protechnic Exeter Limited, a provider of
software solutions to the primary healthcare market. Ascribe joined AIM on 17
December 2004 raising #5.5m before expenses.


The software produced by Ascribe addresses the Audit Commission report 'A
Spoonful of Sugar' published in 2001, which identified potentially up to 1,200
lives and #500 million per year from certain medication errors in UK hospitals
alone could be saved using clinical information systems. Ascribe's system
enables pharmacists to store information about the patients they treat and use
this information to assist in their decision-making. The system also integrates
with stock control procedures. The latest web based product has further enabled
technology to link the information between customers building a solution where
the risk of the above medication errors can be reduced.


Protechnic Exeter supports those who provide care within Primary Care,
Community, Mental Health and Social Care. Its ePEX software is widely used
throughout the United Kingdom and Ireland to provide specialist mental health
systems to support the administration, clinical management and information
activities of the Trusts; and child care systems for interactive scheduling for
vaccinations, immunisations and surveillance, providing a longitudinal record of
patients from birth into adulthood for all community services. Its Exeter
software is widely used by UK GP practices.


After considerable investment in web based solutions, the Group's strategy is to
use this software to enhance its offering, initially to Protechnic Exeter
customers and then to customers of other acquisitions as they are completed and
integrated, delivering a Group capable of addressing the whole medicines
management market.

[stucom] 16/6/2005 09:49

one hopes so,curry,taken a hit on fib 2day! still,sea is given me hope!....lol

[currypasty] 16/6/2005 09:48

looking to take out previous high of 34

[stucom] 15/6/2005 15:35

curry,looks like movement? easy does it!

[currypasty] 15/6/2005 15:25

a bit of action today !

[stucom] 13/6/2005 10:50

curry,dipped in for a few last wek @28.5p.having a good run of late,let's hope it carries on!.....stu

[currypasty] 13/6/2005 10:39

more large buys, and a tick up !

[currypasty] 06/6/2005 08:03

quite a few buys (compared to normal) today, must be that write up !

[stucom] 05/6/2005 14:47

bit of a write up about asp in this mornings Fin. Mail on Sunday.not a holder....yet,but observing....stu

[currypasty] 02/6/2005 07:58

up 2.5 to open this morning !

[currypasty] 01/6/2005 08:44

blue again, something is in the offing !

[ltinvestor] 31/5/2005 15:46

This company has been overlooked by private investors.I expect more earnings enhancing acquisitions over the next 12 months and eventually this company will be acquired by others.

[currypasty] 31/5/2005 15:05

back to 34p ?

[currypasty] 31/5/2005 09:35

making some progress today

[currypasty] 23/5/2005 07:43

RNS Number:6099M
Ascribe plc
23 May 2005


23rd May 2005


Ascribe plc (Ascribe) makes strategic move into Accident and Emergency (A&E)
with the #2.6 million acquisition of Footman Walker Limited (Footman Walker)


The Board of Ascribe (the Board), the health IT group focusing on medicines
management, announces today an important strategic move and expansion of their
offering with the acquisition of Footman Walker, the leading supplier of
information systems into Accident and Emergency and minor injuries units. A
market leader, Footman Walker provides systems into 30% of Accident and
Emergency departments within the UK National Health Service.


The total consideration of #2.6 million, including a deferred element of
#800,000, is to be satisfied by a mixture of cash and new ordinary shares
(further details are provided in Notes to Editors).


In a medical emergency access to information about a patient and their medical
needs, in terms of medicines, is critical. Ascribe's existing IT products
provide the clinician with medication information which, combined with Footman
Walker's system, offers the complete view of the patient's information,
seamlessly, during the treatment of medical emergencies.


In the year ended 30 April 2004, Footman Walker made a profit before tax of
#242,000 on a turnover of #1.24 million. Results for the year ended 30 April
2005 are expected to be ahead of last year. Winning over 80% of advertised new
business means the company is seeing unprecedented growth with a strong order
book. The value of the net assets being acquired is approximately #250,000. The
Board believes that this acquisition will be earnings enhancing during the first
year.


Commenting, Stephen Critchlow, Chief Executive of Ascribe plc, said: "Patient
information systems are a crucial component of the Government's healthcare
agenda and connectivity of inter-departmental patient information is vital,
particularly in the area of A&E where time critical life saving treatments are
undertaken.


The combining of our products addresses this requirement and represents a
significant milestone for Ascribe. The acquisition is earnings enhancing and the
business is expanding in a market where it is the recognised leader. The
management and development team will be a considerable asset to the group as we
continue to deliver on our growth strategy."


Contacts:


Ascribe plc Tel: [phone]

Stephen Critchlow

Chief Executive


Jeremy Lee Tel: [phone]

Group Finance Director



Citigate Dewe Rogerson Tel: [phone]

Ginny Pulbrook

Justin Griffiths


Notes to Editors:


* The consideration comprises (i) an initial element of #1,838,250 to be
satisfied on completion as to #1,038,250 in cash and through the issue of
3,479,260 new ordinary shares in Ascribe to the vendors, and (ii) a deferred
element of up to #800,000 to be satisfied on the first anniversary of
completion as to #200,000 in cash and, at the discretion of Ascribe, through
the issue of new ordinary shares in Ascribe to the value #600,000 (based on
the closing market value of Ascribe's shares in the 3 working days prior to
the first anniversary of completion) or #600,000 in cash dependent upon the
turnover of the Footman Walker group in the year following completion.
Ascribe has today applied to AIM for admission of the 3,479,260 initial
consideration shares, which is expected to become effective on 27 May 2005.


* Ascribe is a health IT group focusing on medicines management through the
development and marketing of software solutions supporting patient, clinical
and business processes to the international healthcare market. The Group
consists of ASC Computer Software Limited, a software supplier to hospital
pharmacy departments internationally and Protechnic Exeter Limited, a
provider of software solutions to the primary healthcare market. Ascribe
joined AIM on 17 December 2004 raising #5.5m before expenses.


The software produced by Ascribe addresses the Audit Commission report 'A
Spoonful of Sugar' published in 2001, which identified potentially up to 1,200
lives and #500 million per year from certain medication errors in UK hospitals
alone could be saved using clinical information systems. Ascribe's system
enables pharmacists to store information about the patients they treat and use
this information to assist in their decision-making. The system also integrates
with stock control procedures. The latest web based product has further enabled
technology to link the information between customers building a solution where
the risk of the above medication errors can be reduced.


Protechnic Exeter supports those who provide care within Primary Care,
Community, Mental Health and Social Care. Its ePEX software is widely used
throughout the United Kingdom and Ireland to provide specialist mental health
systems to support the administration, clinical management and information
activities of the Trusts; and child care systems for interactive scheduling for
vaccinations, immunisations and surveillance, providing a longitudinal record of
patients from birth into adulthood for all community services. Its Exeter
software is widely used by UK GP practices.


After considerable investment in web based solutions, the Group's strategy is to
use this software to enhance its offering, initially to Protechnic Exeter
customers and then to customers of other acquisitions as they are completed and
integrated, delivering a Group capable of addressing the whole medicines
management market.


For further information, please visit:

www.ascribe.com

[currypasty] 10/5/2005 08:25

RNS Number:0763M
Ascribe plc
10 May 2005

10th May 2005

Ascribe plc

Change of Advisers



The Board of Ascribe plc, the health IT group focussing on medicines management,
is pleased to announce both the appointment of Evolution Securities Limited as
their new nominated adviser, broker and financial adviser and Citigate Dewe
Rogerson as their financial public relations adviser with immediate affect.

[currypasty] 10/5/2005 08:24

RNS Number:0766M
Ascribe plc
10 May 2005



10th May 2005



Ascribe plc

Board Appointments



Ascribe plc, the health IT group focusing on medicines management, today
announces the appointments of Chris Moore to the Board as non-executive Chairman
and Mark Woodbridge as non-executive director, with immediate affect.



Chris Moore, aged 50, is currently Chief Executive of Torex Retail plc and
Chairman of retail IT services group XN Checkout. He has extensive plc expertise
with over 20 years experience within the IT sector. Up until its merger with
iSOFT, Chris led the management team of the high profile European healthcare IT
group, Torex PLC, where he built up the company by acquisition and organically,
from a small company with a market capitalisation of #10 million to a #350
million substantial group.



Mark Woodbridge, aged 34, was Group Finance Director of Torex PLC from June 2000
to December 2003, working alongside Chris during the group's transformation from
a small company to a market leader. Previously Mark worked as Financial
Controller for Tarmac plc for five years, two of which were spent in Malaysia.



Commenting on the appointments, Steve Crichlow, Chief Executive, Ascribe plc,
said: "Following our successful listing on AIM in December, the Company has
continued to perform well and is now at the next stage of strategic positioning
and corporate development. Therefore, we are very pleased to welcome Chris and
Mark to the Board of Ascribe plc, both of whom have a wealth of managerial and
business experience which will prove invaluable to us in the forthcoming years."



Commenting on the appointments, Chris Moore said: "Ascribe is a market leading
company, with an excellent product strategy and great potential in the high
growth medicines management sector. We are delighted to be given the opportunity
of working with the team on developing future growth strategy and ensuring
Ascribe's continued success."